Cancer clinical trials in the region Pays de la Loire
440 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Lymphoma
#NCT05947851
#2022-501560-17-01
Required histologic types
B cell lymphoma
Required histologic sub types
Lymphocytic lymphoma
Required central nervous system lesions
None
Treated / Controled
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
Targeted therapy
3 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
CLL & Richter's syndrome
#NCT05947851
#2022-501560-17-01
Required histologic types
CLL (Chronic Lymphocytic Leukemia)
Required central nervous system lesions
None
Treated / Controled
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
Targeted therapy
3 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Colon cancer
#NCT05855200
#2023-503265-27-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Locally Advanced
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
MSS/pMMR
9 recruiting sites
GlaxoSmithKline
Phase 3
Colon cancer
#NCT06107920
#2024-516456-17-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Chemotherapy
Radiotherapy
3 recruiting sites
CHU Rouen
Phase 3
Colon cancer
Rectal cancer
#NCT06293625
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded genetic anomalies
MSI/dMMR
57 recruiting sites
CHU Dijon
Phase 3
Lung cancer
#NCT06793215
#2024-518365-10-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
14 recruiting sites
Hoffmann-La Roche
Phase 3
Lung cancer
#NCT06765109
#2024-517553-26-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ALK
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRAF
EGFR
HER2
HRAS
KRAS G12C
KRAS non G12C
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
11 recruiting sites
Nuvalent Inc.
Phase 3
Lung cancer
#NCT06767514
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
HER2
HRAS
KRAS G12C
KRAS non G12C
MET
NTRK-1/2/3
RET
ROS-1
9 recruiting sites
Summit Therapeutics
Phase 3
Liver and bile duct cancer
#NCT05615818
#2023-508100-38-00
Required histologic sub types
Intrahepatic cholangiocarcinoma
Extrahepatic cholangiocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
35 recruiting sites
UNICANCER
Phase 3
Liver and bile duct cancer
#NCT06282575
#2023-508219-21-00
Required histologic sub types
Intrahepatic cholangiocarcinoma
Extrahepatic cholangiocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Targeted therapy
11 recruiting sites
Jazz Pharmaceuticals